SCHEMBL14737176

SCHEMBL14737176

COc1ccc(-c2cccc3c2CNC3=O)c(OCC(C)(C)OC(=O)C2CCCCC2)c1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.33
HPGD P15428 2/20 0.33
HDAC4 P56524 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
PLK4 O00444 2/20 0.33
ROCK2 O75116 2/20 0.33
NTRK1 P04629 2/20 0.33
MET P08581 2/20 0.33
ROS1 P08922 2/20 0.33
RPS6KB1 P23443 2/20 0.33
EPHA2 P29317 2/20 0.33
AXL P30530 2/20 0.33
FLT4 P35916 2/20 0.33
FLT3 P36888 2/20 0.33
FRK P42685 2/20 0.33
ROCK1 Q13464 2/20 0.33
NTRK2 Q16620 2/20 0.33
TAOK1 Q7L7X3 2/20 0.33
HIPK4 Q8NE63 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14737791 0.99 KDR (0.34) KDRHPGDHDAC4HDAC2HDAC8
SCHEMBL14737799 0.97 KDR (0.34) KDRHPGDHDAC4HDAC2HDAC8
SCHEMBL14737388 0.96 KDR (0.35) KDRHDAC4HDAC2HDAC8PLK4
SCHEMBL14737629 0.92 GSK3B (0.33) KDRHDAC4HDAC2HDAC8PLK4
SCHEMBL2589282 0.87 HDAC4 (0.37) KDRHDAC4HDAC2HDAC8PLK4
SCHEMBL2584840 0.87 HPGD (0.35) KDRHPGDHDAC4HDAC2HDAC8
SCHEMBL2591678 0.87 ALDH1A1 (0.44) HPGDHDAC4HDAC2HDAC8ALDH1A1
SCHEMBL14737342 0.87 ALDH1A1 (0.44) HPGDHDAC4HDAC2HDAC8ALDH1A1
SCHEMBL14737140 0.85 PDE4D (0.37) HDAC4HDAC2HDAC8ALDH1A1TSHR
SCHEMBL2589712 0.85 KMT2A (0.35) KDRHPGDHDAC4HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A KDR 1971/4885HPGD 1088/4885HDAC4 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.